BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22918166)

  • 21. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
    Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
    Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
    Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
    Milione M
    Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
    Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
    Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia.
    Dizdar L; Oesterwind KA; Riemer JC; Werner TA; Mersch S; Möhlendick B; Schütte SC; Verde PE; Raba K; Topp SA; Stoecklein NH; Esposito I; Knoefel WT; Krieg A
    Oncotarget; 2017 Jan; 8(5):8369-8382. PubMed ID: 28039474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances.
    Mohamed A; Strosberg JR
    J Nucl Med; 2019 Jun; 60(6):721-727. PubMed ID: 30737297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
    Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
    J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors.
    Klöppel G; Anlauf M; Perren A
    Endocr Pathol; 2007; 18(3):150-5. PubMed ID: 18058264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
    Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases.
    Zimmermann N; Lazar-Karsten P; Keck T; Billmann F; Schmid S; Brabant G; Thorns C
    Anticancer Res; 2016 Mar; 36(3):921-4. PubMed ID: 26976979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors.
    Galván JA; Astudillo A; Vallina A; Fonseca PJ; Gómez-Izquierdo L; García-Carbonero R; González MV
    Am J Clin Pathol; 2013 Jul; 140(1):61-72. PubMed ID: 23765535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Notch signaling in mouse blastocyst development and hatching.
    Batista MR; Diniz P; Torres A; Murta D; Lopes-da-Costa L; Silva E
    BMC Dev Biol; 2020 Jun; 20(1):9. PubMed ID: 32482162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uniform and Robust Nuclear Expression of HES1 in Neuroendocrine Neoplasms.
    Cui M; Cai Z; Awadallah A; Xin W
    Int J Surg Pathol; 2019 Dec; 27(8):844-851. PubMed ID: 31232134
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel Finding of Paired Box 5 (PAX5) Cytoplasmic Staining in Well-differentiated Rectal Neuroendocrine Tumors (Carcinoids) and Its Diagnostic and Potentially Prognostic Utility.
    Fu Z; Zuo C; Sheehan CE; Patil DT; Lin J; Yang Z; Lee H
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):454-460. PubMed ID: 29561272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.
    Geis C; Fendrich V; Rexin P; Di Fazio P; Bartsch DK; Ocker M; Quint K; Heverhagen AE
    J Surg Res; 2015 Apr; 194(2):388-393. PubMed ID: 25439321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors.
    Kidd M; Modlin IM; Drozdov I
    BMC Genomics; 2014 Jul; 15(1):595. PubMed ID: 25023465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.
    Herrera-Martínez AD; Gahete MD; Sánchez-Sánchez R; Alors-Perez E; Pedraza-Arevalo S; Serrano-Blanch R; Martínez-Fuentes AJ; Gálvez-Moreno MA; Castaño JP; Luque RM
    Clin Transl Gastroenterol; 2018 Oct; 9(10):196. PubMed ID: 30297816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
    Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.